BRPI0822775A2 - Método de obtenção de uma proteína heteróloga, purificada, biologicamente ativa. - Google Patents

Método de obtenção de uma proteína heteróloga, purificada, biologicamente ativa.

Info

Publication number
BRPI0822775A2
BRPI0822775A2 BRPI0822775-6A BRPI0822775A BRPI0822775A2 BR PI0822775 A2 BRPI0822775 A2 BR PI0822775A2 BR PI0822775 A BRPI0822775 A BR PI0822775A BR PI0822775 A2 BRPI0822775 A2 BR PI0822775A2
Authority
BR
Brazil
Prior art keywords
obtaining
biologically active
heterologous protein
purified biologically
active heterologous
Prior art date
Application number
BRPI0822775-6A
Other languages
English (en)
Inventor
Partha Hazra
Nitesh Dave
Vivekanandan Kannan
Sanjay Tiwari
Anuj Goel
Harish Iyer
Nita Roy
Krishnamurthy Venkatesan
Anoop Vasudevan
Anupama Jagadish
Goldy Sachdev
Mukesh Babuappa Patale
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of BRPI0822775A2 publication Critical patent/BRPI0822775A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0822775-6A 2008-02-19 2008-04-03 Método de obtenção de uma proteína heteróloga, purificada, biologicamente ativa. BRPI0822775A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN420CH2008 2008-02-19
PCT/IN2008/000219 WO2009104199A1 (en) 2008-02-19 2008-04-03 A method of obtaining purified heterologous insulins expressed in yeast

Publications (1)

Publication Number Publication Date
BRPI0822775A2 true BRPI0822775A2 (pt) 2015-06-30

Family

ID=40985112

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822775-6A BRPI0822775A2 (pt) 2008-02-19 2008-04-03 Método de obtenção de uma proteína heteróloga, purificada, biologicamente ativa.

Country Status (11)

Country Link
US (1) US8802816B2 (pt)
EP (1) EP2242767A4 (pt)
JP (2) JP5781308B2 (pt)
KR (1) KR101556514B1 (pt)
CN (1) CN102015762B (pt)
BR (1) BRPI0822775A2 (pt)
IL (1) IL207646A (pt)
MX (1) MX2010009033A (pt)
MY (1) MY161892A (pt)
RU (1) RU2495131C2 (pt)
WO (1) WO2009104199A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100098B2 (en) 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
WO2010088268A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
WO2010088300A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Crystalline insulin-conjugates
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
US8623345B2 (en) 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
MX2012000087A (es) * 2009-07-09 2012-02-28 Biocon Ltd Metodo cromatografico basado en gradiente no lineal preparativo y productos purificados del mismo.
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
EP2598522A4 (en) 2010-07-28 2014-11-12 Smartcells Inc RECOMBINANT LKTINE, BINDING POINT MODIFIED LECTIN AND APPLICATIONS THEREOF
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
WO2012115638A1 (en) * 2011-02-23 2012-08-30 Elona Biotechnologies Glargine proinsulin compositions and methods of producing glargine insulin analogs therefrom
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2831262B1 (en) 2012-03-29 2018-02-14 Biocon Limited Secretion of functional insulin glargine directly into the culture medium through over expression of kex2p intracellularly
EP2844274B1 (en) * 2012-05-01 2019-03-20 Novo Nordisk A/S Pharmaceutical composition
CN103833828B (zh) * 2012-11-21 2017-01-11 广东东阳光药业有限公司 一种甘精胰岛素前体蛋白的提取方法
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
CN102994600A (zh) * 2012-12-11 2013-03-27 鲁南新时代生物技术有限公司 甘精胰岛素前体的酶切转化方法
UA117480C2 (uk) 2013-04-03 2018-08-10 Санофі Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
KR20160065930A (ko) 2013-10-04 2016-06-09 머크 샤프 앤드 돔 코포레이션 글루코스-반응성 인슐린 접합체
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN106282274B (zh) * 2015-06-29 2021-05-11 宜昌东阳光长江药业股份有限公司 一种胰岛素前体蛋白的毕赤酵母高密度发酵方法
JP2019501982A (ja) * 2015-10-30 2019-01-24 積水化学工業株式会社 熱伝導体、ヒートシンク、ヒートスプレッダ、ヒートスプレッダの製造方法、及び熱伝導体の製造方法
CN108463243B (zh) 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
RU2736358C2 (ru) * 2015-12-09 2020-11-16 Общество С Ограниченной Ответственностью "Синбио" Способ очистки полисиалированного инсулина человека
PL239062B1 (pl) * 2016-01-22 2021-11-02 Inst Biotechnologii I Antybiotykow Sposób wytwarzania insuliny i jej pochodnych
CN105585628B (zh) * 2016-01-28 2019-02-01 通化东宝药业股份有限公司 一种甘精胰岛素的制备方法及其制备的甘精胰岛素
CN108047301A (zh) * 2017-12-08 2018-05-18 福州博中技术开发有限公司 一种纯化有机酸肽的方法
CN108148114B (zh) * 2017-12-08 2020-05-15 珠海冀百康生物科技有限公司 一种提高重组小分子蛋白表达量的串联前导肽及方法
CN112105635A (zh) * 2018-06-18 2020-12-18 联合化学实验室有限公司 用于重组蛋白的更高表达的前导序列
KR102646845B1 (ko) 2018-08-08 2024-03-14 주식회사 대웅제약 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
CN113166198B (zh) * 2018-08-20 2025-01-03 拜康生物制品有限公司 用于纯化胰岛素类似物的色谱方法
CN109735589B (zh) * 2019-01-02 2020-07-10 珠海冀百康生物科技有限公司 一种胰岛素DesB30的制备方法
WO2020144606A1 (en) * 2019-01-10 2020-07-16 Biocon Limited Preparative crystallization of recombinant human insulin
CN112341535A (zh) * 2019-08-07 2021-02-09 中国科学院大连化学物理研究所 一种采用离子交换色谱法分离纯化制备胰岛素的方法
CN113121637B (zh) * 2020-01-15 2022-06-14 鲁南制药集团股份有限公司 一种重组蛋白的分离纯化方法
CN113773399B (zh) * 2020-06-09 2023-05-12 宁波鲲鹏生物科技有限公司 一种甘精胰岛素衍生物及其应用
WO2022044030A1 (en) * 2020-08-31 2022-03-03 Usv Private Limited An improved process for fmoc synthesis of etelcalcetide
CN113105536B (zh) * 2020-09-11 2023-07-18 美药星（南京）制药有限公司 一种新甘精胰岛素原及其制备甘精胰岛素的方法
CN114805610B (zh) * 2022-06-23 2022-10-04 北京惠之衡生物科技有限公司 一种高表达甘精胰岛素前体的重组基因工程菌及其构建方法
CN120309711A (zh) * 2025-06-17 2025-07-15 杭州思诺达医药科技有限责任公司 一种替度鲁肽的纯化方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028120C2 (de) * 1990-09-05 1996-09-19 Hoechst Ag Verfahren zur Reinigung von Insulin und/oder Insulinderivaten
HU219674B (hu) * 1992-08-28 2001-06-28 Novo Nordisk A/S Glukagon-receptort kódoló DNS-molekulák, glukagon-receptor peptidek, glukagon-receptort blokkoló monoklonális ellenanyagok, és eljárások előállításukra
ATE203998T1 (de) * 1993-04-27 2001-08-15 Hoechst Ag Amorphe monosphärische formen von insulinderivaten
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
ES2245824T3 (es) * 1998-04-15 2006-01-16 Novo Nordisk A/S Nuevo proceso de separacion de proteinas utilizando un eluyente que contiene ca++.
AR025646A1 (es) * 2000-09-13 2002-12-04 Beta Lab Sa Cepa de levaduras metilotroficas recombinantes productoras de un precursor de insulina, construcciones de adn y metodo para obtener la cepa.
EP1343903B1 (en) * 2000-12-21 2007-11-14 Thromb-X N.V. A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
EP1692168B1 (en) * 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
CN1873006A (zh) * 2005-05-30 2006-12-06 上海新生源医药研究有限公司 一种重组人胰岛素原的生产方法
AU2006291780B2 (en) * 2005-09-14 2011-12-08 F. Hoffmann-La Roche Ag Cleavage of precursors of insulins by a variant of trypsin
ES2546016T3 (es) * 2005-10-13 2015-09-17 Biocon Limited Procedimiento para la preparación de conjugados de insulina
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende

Also Published As

Publication number Publication date
JP6077027B2 (ja) 2017-02-08
CN102015762A (zh) 2011-04-13
EP2242767A1 (en) 2010-10-27
US8802816B2 (en) 2014-08-12
RU2495131C2 (ru) 2013-10-10
MX2010009033A (es) 2010-12-21
RU2010138656A (ru) 2012-03-27
KR20100117612A (ko) 2010-11-03
MY161892A (en) 2017-05-15
WO2009104199A1 (en) 2009-08-27
US20110236925A1 (en) 2011-09-29
JP5781308B2 (ja) 2015-09-16
JP2015083019A (ja) 2015-04-30
IL207646A (en) 2016-08-31
KR101556514B1 (ko) 2015-10-02
IL207646A0 (en) 2010-12-30
EP2242767A4 (en) 2011-04-06
JP2011514151A (ja) 2011-05-06
CN102015762B (zh) 2015-03-18

Similar Documents

Publication Publication Date Title
BRPI0822775A2 (pt) Método de obtenção de uma proteína heteróloga, purificada, biologicamente ativa.
BRPI1011414A2 (pt) "método."
BRPI1008634A2 (pt) "um meio de conexão, um método de fabricação do mesmo e uma conexão de material".
SMT201700529T1 (it) Metodi per un'aumentata produzione di proteine
BRPI0815036A2 (pt) Método de produção de proteína heterogêneas
PL2190883T3 (pl) Sposób obróbki biomasy
BRPI0810482A2 (pt) Métodos de produção de proteína usando compostos antissenescência
LT3415515T (lt) Metil-{4,6-diamino-2-[1-(2-fluorbenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamato gamybos būdas
BRPI0814466A2 (pt) Método.
BRPI1008021A2 (pt) Método para fabricação de 2,6-dioxabiciclo-(3.3.0)-octano-4,8-diona
BR112012004593A2 (pt) "método"
DK2307543T3 (da) Forbedret proteinekspressionssystem
BRPI0910122A2 (pt) "método de produção de biomassa de levedura"
BRPI0909908A2 (pt) implante de válvula cardíaca
FR2929502B1 (fr) Implant nucleique.
BRPI0916499A2 (pt) método de produção de biomassa
BRPI0920779A2 (pt) método de produção de óleo biológico.
BRPI1009418A2 (pt) nanocapsula de proteina, metodo de pdroduzir uma nanocapsula, e metodo de distribuir uma proteina
BRPI0917629A2 (pt) método de separação de ar.
BRPI0920246A2 (pt) método de preparação de alfa-beta peptídios biologicamente ativos.
BRPI0810710A2 (pt) Método para estabilização de uma proteína.
DK3115370T3 (da) Biologisk aktive peptider
ES2386734T8 (es) Ácidos fenoxiacéticos como activadores de PPAR-delta.
PL2160432T3 (pl) Sposób wytwarzania poliamidów
BRPI0905928A2 (pt) "método de produção de ácido lático"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2336 DE 13/10/2015

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/04/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.